Back to Journals » Clinical Ophthalmology » Volume 14

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date

Authors Chen ER, Kaiser PK

Received 10 March 2020

Accepted for publication 4 May 2020

Published 19 May 2020 Volume 2020:14 Pages 1349—1355

DOI https://doi.org/10.2147/OPTH.S194234

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Eric R Chen,1 Peter K Kaiser2

1School of Medicine, Case Western Reserve University, Cleveland, OH, USA; 2Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

Correspondence: Peter K Kaiser
Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3-125, Cleveland, OH 44195, USA
Tel +1 (216) 444-6702
Email kaiserp@ccf.org

Abstract: Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults worldwide. The advent of intravitreal neutralization of vascular endothelial growth factor (VEGF) has revolutionized the management of patients with neovascular AMD, but current anti-VEGF therapies carry a high threshold of patient burden. The ranibizumab port delivery system (PDS) is an implanted, refillable reservoir that continuously supplies the anti-VEGF medication ranibizumab directly into the vitreous, eliminating the need for frequent intravitreal injections. It has most recently been evaluated in the Phase II LADDER trial demonstrating the efficacy and safety of the PDS, with Phase III trials currently underway. This review presents both the promise and drawbacks of the PDS in the treatment of AMD from the current literature.

Keywords: neovascular age-related macular degeneration, ranibizumab, port delivery system, vascular endothelial growth factor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]